Wells Fargo Upgrades Watson Pharmaceuticals (WPI) to Outperform; Actavis Acquisition Adds Growth Prospects
Tweet Send to a FriendGet Alerts WPI Hot Sheet
Price: $85.73 --0%
Rating Summary:
14 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
14 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade WPI Now!
Wells Fargo upgraded Watson Pharmaceuticals (NYSE: WPI) from Market Perform to Outperform, raising price target range from $75-79 to $84-90.
Analyst, Michael Tong, said, "We have had a positive outlook on WPI's proposed Actavis acquisition. However, we were concerned about lofty 2013 cash EPS expectation (about $8) for Newco, and the share price immediately following the Actavis announcement left very little margin for error in our view. Upon further analysis, we are now more comfortable with Newco's ability to approach the EPS expectation. With WPI shares having pulled back since then, we think the reward/risk profile has turned sufficiently favorable to warrant an upgrade."
Tong raises FY13 EPS (standalone) estimate from $6.05 to $6.22...believe Newco should be able to approach the $8 EPS expectation in 2013.
For an analyst ratings summary and ratings history on Watson Pharmaceuticals click here. For more ratings news on Watson Pharmaceuticals click here.
Shares of Watson Pharmaceuticals closed at $70.71 yesterday, with a 52 week range of $55.00-$77.73.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Michael Tong, said, "We have had a positive outlook on WPI's proposed Actavis acquisition. However, we were concerned about lofty 2013 cash EPS expectation (about $8) for Newco, and the share price immediately following the Actavis announcement left very little margin for error in our view. Upon further analysis, we are now more comfortable with Newco's ability to approach the EPS expectation. With WPI shares having pulled back since then, we think the reward/risk profile has turned sufficiently favorable to warrant an upgrade."
Tong raises FY13 EPS (standalone) estimate from $6.05 to $6.22...believe Newco should be able to approach the $8 EPS expectation in 2013.
For an analyst ratings summary and ratings history on Watson Pharmaceuticals click here. For more ratings news on Watson Pharmaceuticals click here.
Shares of Watson Pharmaceuticals closed at $70.71 yesterday, with a 52 week range of $55.00-$77.73.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- UPDATE: Leerink Swann Upgrades Bristol-Myers Squibb Co. (BMY) to Outperform
- Deutsche Bank Raises PT on Access Midstream Partners (ACMP) to $57
Create E-mail Alert Related Categories
Analyst EPS Change, Analyst EPS View, Analyst PT Change, UpgradesRelated Entities
Wells Fargo
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
